Complicated community acquired pneumonia in childhood: Different types, clinical course, and outcome

Pediatr Pulmonol. 2017 Feb;52(2):247-254. doi: 10.1002/ppul.23523. Epub 2016 Jul 8.

Abstract

The incidence of pediatric community acquired complicated pneumonia (PCACP) is increasing. Questions addressed: Are different types of PCACP one disease? How do different treatment protocols affect the outcome?

Methods: Retrospective analysis of medical records of PCACP hospitalizations in the three major hospitals in Jerusalem in the years 2001-2010 for demographics, clinical presentation, management, and outcome.

Results: Of the 144 children (51% aged 1-4 years), 91% of Jewish origin; 40% had para-pneumonic effusion (PPE), 40% empyema (EMP), and 20% necrotizing pneumonia (NP). Bacterial origin was identified in 42% (empyema 79%, P = 0.009), most common S. pneumoniae (32%), group A streptococcus (9%). Patients with EMP, compared to PPE and NP, were less likely to receive prior antibiotic treatment (35% vs. 57% and 59%, respectively, P = 0.04). Mean hospitalization was longer in patients with NP followed by EMP and PPE (16.4 ± 10.6, 15.2 ± 7.9, and 12.7 ± 4.7 days, respectively), use of fibrinolysis was not associated with the outcome. All children had recovered to discharge regardless of antibiotic therapy or fibrinolysis.

Answer: NP is a more severe disease with prolonged morbidity and hospitalization in spite of prior antibiotic treatment. All types had favorable outcome regardless of treatment-protocol. Complicated pneumonia has an ethnic predominance. Pediatr Pulmonol. 2017;52:247-254. © 2016 Wiley Periodicals, Inc.

Keywords: empyema; necrotizing pneumonia; para-pneumonic effusion; pediatric community acquired complicated pneumonia.

MeSH terms

  • Adolescent
  • Anti-Bacterial Agents / therapeutic use*
  • Child
  • Child, Preschool
  • Community-Acquired Infections / complications
  • Community-Acquired Infections / drug therapy*
  • Community-Acquired Infections / epidemiology
  • Community-Acquired Infections / microbiology
  • Empyema, Pleural / etiology
  • Female
  • Hospitalization
  • Humans
  • Incidence
  • Infant
  • Israel
  • Male
  • Pleural Effusion / etiology
  • Pneumonia / complications
  • Pneumonia / drug therapy
  • Pneumonia / epidemiology
  • Pneumonia / microbiology
  • Pneumonia, Necrotizing / complications
  • Pneumonia, Necrotizing / drug therapy*
  • Pneumonia, Necrotizing / epidemiology
  • Pneumonia, Necrotizing / microbiology
  • Pneumonia, Pneumococcal / complications
  • Pneumonia, Pneumococcal / drug therapy*
  • Pneumonia, Pneumococcal / epidemiology
  • Pneumonia, Pneumococcal / microbiology
  • Retrospective Studies
  • Streptococcal Infections / complications
  • Streptococcal Infections / drug therapy
  • Streptococcal Infections / epidemiology
  • Streptococcal Infections / microbiology
  • Streptococcus pneumoniae
  • Streptococcus pyogenes
  • Survival Rate

Substances

  • Anti-Bacterial Agents